40
NISTmAb, the world’s first standardized monoclonal antibody has become a valuable tool for biomanufacturers developing new biologic therapies for cancers, autoimmune disorders and infectious diseases. Although the molecule has been precisely characterized, the current proprietary method for its production has not. In a new article, researchers describe how they have taken the first step to solve this dilemma: engineering three mouse cell lines to produce nonproprietary versions of NISTmAb that closely resemble the characteristics of the original reference material.